This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Methadone

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Methadone is a synthetic compound with pharmacologic action similar to that of morphine and heroin, almost equal in addiction liability.

The hydrochloride is used as an antitussive and analgesic and as a substitute narcotic in the management of opiate withdrawal, since it is longer acting than most opiates.

It is substituted for an abused opiate and then the dose is reduced.

  • methadone is available as an oral solution (1 mg/ml), an oral concentrate (10 mg/ml), tablets or injectable ampoules
  • methadone has a long elimination half-life (usually 20-37 hours), which allows for a once-daily dosing schedule
  • methadone appears to have no serious long-term side effects associated with chronic administration (1)
  • in the context of opioid dependence management, and using a methadone maintenance regimen, the drug does not have the pronounced narcotic effects seen with shorter-acting opioids such as illicit diamorphine
  • interactions with other drugs
    • elimination of methadone is increased by some drugs including including rifampicin, phenytoin, phenobarbital and some antiviral drugs used in the treatment of HIV infection
    • rate of elimination is reduced by drugs such as fluvoxamine and fluoxetine

Conult the Summary of Product Characteristics before prescribing this drug.

Notes:

  • methadone or buprenorphine should be offered as the first-line treatment in opioid detoxification. When deciding between these medications, healthcare professionals should take into account (2):
    • whether the service user is receiving maintenance treatment with methadone or buprenorphine; if so, opioid detoxification should normally be started with the same medication
    • the preference of the service user
  • a review of 83 RCTs & 193 observational studies (total > 1 million participants) found, at timepoints beyond 1 month, retention in treatment was better for methadone vs buprenorphine (3)
    • also found evidence of reduced cocaine use, cravings, anxiety, and cardiac dysfunction, as well as increased treatment satisfaction among people receiving buprenorphine compared with methadone
    • evidence of reduced hospitalisation and alcohol use in people receiving methadone
    • note though that most comparisons were based on small numbers of studies
  • acupuncture for methadone reduction (4):
    • study evidence showed that eight weeks of acupuncture were superior to sham acupuncture in reducing methadone dose and decreasing opioid craving
      • more patients reduced their methadone dose by ≥20% with acupuncture vs sham acupuncture
      • acupuncture also reduced opioid craving

Reference:

  1. NICE (January 2007).Methadone and buprenorphine for the management of opioid dependence
  2. NICE (July 2007).Drug misuse - Opioid detoxification
  3. Degenhardt L et al. Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies. Lancet Psychiatry May 8th 2023.
  4. Lu L et al. Effect of Acupuncture for Methadone Reduction : A Randomized Clinical Trial. Ann Intern Med. 2024 Jul 9. doi: 10.7326/M23-2721.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.